The ever-escalating cost of healthcare has made it difficult for most people to access health care services. Governments are, therefore forced to step in and control prices to ensure universal access. Various strategies can be used to determine the cost of medicines, and IRP is an emerging system in this sector. When it comes to International Reference Pricing China and Japan stand to gain a lot due to their economic and geographic similarities. For more details on how these two countries can benefit from this system, read on.
Such a system ensures a streamlined cost of healthcare. Disparities in charges often exist where there is no control. For example, the same drug might be sold by a big margin between two different regions in the same country. With this system, however, the price of a drug is guaranteed to be the same whether you are in Eastern or western China.
There is increased market access. The system indicates clearly the amount the patient is allowed to pay. Any excesses are handled by the government or insurance agents, depending on the country's policies. This encourages people to seek medical services as they are certain that they will not be left penniless by the time they come back from the hospital.
Companies no longer have monopoly over prices. While drug manufacturers still hold a considerable grip on the price rod, they are no longer lone rangers in the game. There are deep consultations and clear guidelines on prices. Hence, they should already know how much a particular drug is likely to cost even before it is released to the market.
Patients also stand to get better treatment. Most patients keep away from hospitals because they know that costs are way beyond their reach. However, when prices are capped, there is a maximum amount that the patent can spend. This will increase their confidence in treatment and increase access.
Referencing is critical in reducing the prices of medicines. There are many ways in which governments can regulate the costs of medicines. However, IRP is found to be the most suitable because it considers several issues to ensure that while patients benefit, the manufactures also do not lose.
This is a relatively simple method. For the implementation of this system, countries only need little information such as the costs of the same medicines in other countries. The countries used for referencing are normally those that share similar economic environments or geographic similarities. It is assumed that referencing countries have fairer and competitive prices.
Implementation is cheap. For a system to be implemented with ease, it should be easy to replicate. The International Reference Pricing relies heavily on communication. There is little resource usage after development. The manufacturers and stakeholders in the industry are simply communicated to the polices for them to implement.
This system is slowly gaining ground across the globe. Countries such as China and Japan, which have implemented it can have something to teach others. So far, evidence suggests that it is successful and appropriate, particularly in capitalistic markets.
Such a system ensures a streamlined cost of healthcare. Disparities in charges often exist where there is no control. For example, the same drug might be sold by a big margin between two different regions in the same country. With this system, however, the price of a drug is guaranteed to be the same whether you are in Eastern or western China.
There is increased market access. The system indicates clearly the amount the patient is allowed to pay. Any excesses are handled by the government or insurance agents, depending on the country's policies. This encourages people to seek medical services as they are certain that they will not be left penniless by the time they come back from the hospital.
Companies no longer have monopoly over prices. While drug manufacturers still hold a considerable grip on the price rod, they are no longer lone rangers in the game. There are deep consultations and clear guidelines on prices. Hence, they should already know how much a particular drug is likely to cost even before it is released to the market.
Patients also stand to get better treatment. Most patients keep away from hospitals because they know that costs are way beyond their reach. However, when prices are capped, there is a maximum amount that the patent can spend. This will increase their confidence in treatment and increase access.
Referencing is critical in reducing the prices of medicines. There are many ways in which governments can regulate the costs of medicines. However, IRP is found to be the most suitable because it considers several issues to ensure that while patients benefit, the manufactures also do not lose.
This is a relatively simple method. For the implementation of this system, countries only need little information such as the costs of the same medicines in other countries. The countries used for referencing are normally those that share similar economic environments or geographic similarities. It is assumed that referencing countries have fairer and competitive prices.
Implementation is cheap. For a system to be implemented with ease, it should be easy to replicate. The International Reference Pricing relies heavily on communication. There is little resource usage after development. The manufacturers and stakeholders in the industry are simply communicated to the polices for them to implement.
This system is slowly gaining ground across the globe. Countries such as China and Japan, which have implemented it can have something to teach others. So far, evidence suggests that it is successful and appropriate, particularly in capitalistic markets.
About the Author:
Discover all the essential facts about the international reference pricing China and Japan by reading more about this topic online. Get quick access to our main website at http://www.theauricgroup.com/about.